id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-293543-87ulnpdm	Shalhoub, Sarah	Interferon beta-1b for COVID-19	2020-05-10		.txt	text/plain	957	57	53	8 In The Lancet, Ivan Fan-Ngai Hung and colleagues 9 present the results of an open-label, randomised, phase 2 trial that examined the effect of a triple combination regimen of interferon beta-1b 8 million international units (0·25 mg) on alternate days, lopinavir 400 mg plus ritonavir 100 mg every 12 h, and ribavirin 400 mg every 12 h, compared with lopinavir 400 mg plus ritonavir 100 mg every 12 h alone. However, as the authors acknowledge, future studies to examine the efficacy of interferon beta-1b alone or in combination with other drugs to treat severe or critically ill patients with confirmed COVID-19 compared with placebo are warranted. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial	./cache/cord-293543-87ulnpdm.txt	./txt/cord-293543-87ulnpdm.txt